157 related articles for article (PubMed ID: 37530159)
1. Montelukast influence on kidney in experimental induced diabetes mellitus.
Gales C; Stoica B; Nechifor M; Rusu-Zota G
Pak J Pharm Sci; 2023 Mar; 36(2):507-513. PubMed ID: 37530159
[TBL] [Abstract][Full Text] [Related]
2. Montelukast Influence on Lung in Experimental Diabetes.
Gales C; Stoica B; Rusu-Zota G; Nechifor M
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792932
[No Abstract] [Full Text] [Related]
3. Magnesium and other bivalent cations influence upon sodium montelukast effect in experimental-induced thermoalgesia.
Nechifor M; Cuciureanu M; Chelarescu D; Ciubotariu D; Pascu M
Magnes Res; 2008 Mar; 21(1):38-42. PubMed ID: 18557132
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of leukotriene receptor antagonist montelukast on smoking-induced lung injury in Wistar rats.
Yüksel H; Ozbilgin K; Coskun S; Tuglu I
Acta Med Okayama; 2003 Feb; 57(1):13-9. PubMed ID: 12765219
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney.
Otunctemur A; Ozbek E; Cekmen M; Cakir SS; Dursun M; Polat EC; Somay A; Ozbay N
Ren Fail; 2013; 35(3):403-10. PubMed ID: 23342977
[TBL] [Abstract][Full Text] [Related]
6. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
7. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone.
Murai A; Abe M; Hayashi Y; Sakata N; Katsuragi T; Tanaka K
J Pharmacol Exp Ther; 2005 Feb; 312(2):432-40. PubMed ID: 15470084
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats.
Otunctemur A; Ozbek E; Cakir SS; Dursun M; Cekmen M; Polat EC; Ozcan L; Somay A; Ozbay N
Int Braz J Urol; 2015; 41(2):279-87. PubMed ID: 26005969
[TBL] [Abstract][Full Text] [Related]
9. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
11. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
[TBL] [Abstract][Full Text] [Related]
12. Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.
Sener G; Sakarcan A; Sehirli O; Ekşioğlu-Demiralp E; Sener E; Ercan F; Gedik N; Yeğen BC
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):257-67. PubMed ID: 17499745
[TBL] [Abstract][Full Text] [Related]
13. Influence of montelukast on cisplatin-induced experimental acute renal failure.
Teslariu O; Nechifor M; Plămădeală P; Miron IC
Rev Med Chir Soc Med Nat Iasi; 2014; 118(3):612-7. PubMed ID: 25341273
[TBL] [Abstract][Full Text] [Related]
14. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress.
Cikler E; Ersoy Y; Cetinel S; Ercan F
Acta Histochem; 2009; 111(2):112-8. PubMed ID: 18617226
[TBL] [Abstract][Full Text] [Related]
15. Montelukast protects against renal ischemia/reperfusion injury in rats.
Sener G; Sehirli O; Velioğlu-Oğünç A; Cetinel S; Gedik N; Caner M; Sakarcan A; Yeğen BC
Pharmacol Res; 2006 Jul; 54(1):65-71. PubMed ID: 16584888
[TBL] [Abstract][Full Text] [Related]
16. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites.
Mechiche H; Naline E; Candenas L; Pinto FM; Birembault P; Advenier C; Devillier P
Clin Exp Allergy; 2003 Jul; 33(7):887-94. PubMed ID: 12859443
[TBL] [Abstract][Full Text] [Related]
17. Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects.
Mansour RM; Ahmed MAE; El-Sahar AE; El Sayed NS
Toxicol Appl Pharmacol; 2018 Nov; 358():76-85. PubMed ID: 30222980
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
Holma R; Salmenperä P; Riutta A; Virtanen I; Korpela R; Vapaatalo H
Eur J Pharmacol; 2001 Oct; 429(1-3):309-18. PubMed ID: 11698051
[TBL] [Abstract][Full Text] [Related]
19. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Venugopal N; Acharya P; Zarei M; Talahalli RR
Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
[TBL] [Abstract][Full Text] [Related]
20. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism.
Langlois A; Ferland C; Tremblay GM; Laviolette M
J Allergy Clin Immunol; 2006 Jul; 118(1):113-9. PubMed ID: 16815146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
